

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial

Sheikh SZ, Scheinberg MA, Wei JCC, Tegzova D, Stohl W, de Toledo RA, Mucenic T, Banfi MRA, Maksimowicz-McKinnon K, Abud-Mendoza C, Navarra S, Garcia M, Garcia-De La Torre I, Ros JO, Levy RA, Bass DL, Terrés JR, Punwaney R, Harris J, Nami A, Pierce A, Thorneloe KS, Ji B, Roth DA.

Lancet. Rheumatology
2021; 3(2):e122-e130

ARTICLE IDENTIFIERS

DOI: 10.1016/S2665-9913(20)30355-6

PMID: unavailable

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: 2021229576

pISSN: not available

eISSN: 2665-9913

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.